2) Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (includes CLL and SLL)
Purpose: To determine whether ublituximab is safe and effective in patients with relapsed or refractory B-cell lymphoma who were previously treated with rituximab
Thanks Neil, there does seem to be a lot going on. Dr Sharman's blog is really helping to translate the new work and approaches in an understandable way. The landscape is changing we are fortunate to have someone so able to convey thoughts and map this for us.
Your post reminds me of words spoken at recent group meetings by clinical researchers. It is going to become increasingly important to have a consultant with a special interest in CLL on your team able to navigate the growing number of clinical trials available at research hospitals.
I have never met Dr Sharman, but have the highest regard for him based on the amount of comitment he makes to building a bridge between the patient and the medical world he is a part of through his blogs. he goes into great detail on every aspect of CLL and to have someone who is highly placed in the treatment and design of treatments who reaches out and explain in a clear way to CLLers. I like his candid comments and also the fact he holds out hope to the frightened sufferer that good things are coming. His blog is a must read
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.